Taiho Pharmaceutical Co. Ltd.'s cancer pipeline consists of both chemotherapeutics and targeted therapies, along with programs in-licensed specifically for the Japanese and/or other Asian markets. The company plans to use a pair of late-stage chemotherapeutics, S-1 and TAS-102, to begin building a development and marketing infrastructure in the U.S. and Europe to benefit the company's early stage pipeline of targeted agents. Taiho is a wholly owned subsidiary of